Patent ID: 8318756

Claim:
A method for treating cancer in a patient, wherein the cancer is a cancer type in which 5-FU or 5-FU prodrugs have activity, comprising first administering a DPD inhibitor, wherein the DPD inhibitor is eniluracil and the eniluracil is administered at a dose between about 2.5-5 mg/m 2 , and 4-24 hours thereafter administering 5-FU or a 5-FU prodrug, wherein the 5-FU or 5-FU prodrug is administered at a dose such that at its time of administration the 5-FU or 5-FU prodrug is present in the patient in at least 5-fold excess of the DPD inhibitor to minimize the extent to which the DPD inhibitor can interfere with metabolic activation of the 5-FU or the 5-FU generated from the 5-FU prodrug and compromise 5-FU antitumor activity.